Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 2

A Feasibility Trial to Investigate the Safety and Between-group Effect Size of STIMULAN VG and Standard of Care (SoC) in Participants With Diabetic Foot Osteomyelitis

NCT05539963 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this trial is to evaluate the safety and between-group effect size of STIMULAN VG compared to SoC treatment in patients with diabetic foot osteomyelitis (DFO).

Interventions

  • DRUG STIMULAN VG
  • DRUG Systemic Antibiotics

Study Locations (10)

Arizona

  • Titan Clinical Research — Mesa
  • Axsendo Clinical Research — Phoenix
  • Perseverance Research Center, LLC — Scottsdale
  • Advanced Footcare LLC — Scottsdale

North Carolina

  • UNC School Medicine — Chapel Hill
  • Seaside Clinical Research Institute — Wilmington

Arkansas

  • NEA Baptist Clinic — Jonesboro

Nevada

  • Viable Clinical Research — Henderson

New Jersey

  • Equitable Health Partners - NJ — Mountainside

New York

  • Mount Sinai West — New York

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2023-01-23
Est. Completion 2025-12-30
Phase Phase 2

Sponsor

Biocomposites

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05539963

The ClinicalTrials.gov registry entry for NCT05539963 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biocomposites, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Diabetic Foot Osteomyelitis appearing as the primary indexed condition, and to 2 interventions — of which STIMULAN VG is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05539963 reports 10 study locations spanning 6 distinct geographic areas — top geographies include Arizona, North Carolina, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05539963 about?

NCT05539963 is a clinical study titled "A Feasibility Trial to Investigate the Safety and Between-group Effect Size of STIMULAN VG and Standard of Care (SoC) in Participants With Diabetic Foot Osteomyelitis". The purpose of this trial is to evaluate the safety and between-group effect size of STIMULAN VG compared to SoC treatment in patients with diabetic foot osteomyelitis (DFO).

What is the current status of trial NCT05539963?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2023-01-23. Estimated completion is 2025-12-30.

What conditions does trial NCT05539963 study?

This clinical trial studies the following conditions: Diabetic Foot Osteomyelitis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05539963?

The interventions under investigation include: STIMULAN VG (DRUG), Systemic Antibiotics (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05539963?

This trial is sponsored by Biocomposites, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05539963 being conducted?

This trial has 10 study locations across Arizona, Arkansas, Nevada, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial